Express News | Needham Reiterates Buy on Immuneering, Maintains $15 Price Target

Moomoo 24/7Apr 12 06:33 ET

Analysts' Opinions Are Mixed on These Healthcare Stocks: Enlivex (ENLV), MacroGenics (MGNX) and Immuneering (IMRX)

TipRanksApr 12 06:30 ET

Immuneering Presented Preclinical Data At AACR Annual Meeting For Ongoing Phase 2a Clinical Trial Of IMM-1-104 In RAS-Mutated Advanced Or Metastatic Solid Tumors

Globe Newswire- Preclinical data presented at AACR demonstrate that combining IMM-1-104 with chemotherapies used in the treatment of first-line pancreatic cancer yielded deeper and more durable tumor

BenzingaApr 9 12:04 ET

IMM-1-104 Is Synergistic With Chemotherapy in Pancreatic Cancer Models

CAMBRIDGE, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today presented preclinical data at the American Association for Cancer Research (AACR) Annual Meeting, which the company views as supportive of its ongoing Phase 2a clinical trial of IMM-1-104 in RAS-mutated advanced or metastatic solid tumors.

GlobeNewswireApr 9 12:00 ET

Immuneering(IMRX.US) 10% Shareholder Sells US$1.16 Million in Common Stock

$Immuneering(IMRX.US)$ 10% Shareholder Cormorant Asset Management, LP sold 400K shares of Common Stock on Apr 1, 2024 at an average price of $2.9 for a total value of $1.16 million. This transaction i

moomoo NewsApr 3 18:17 ET

Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference

PDF Version CAMBRIDGE, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF

ImmuneeringApr 3 00:00 ET